Trial Profile
A Double-Blind, Mulitcenter, Placebo-Controlled, Flexible-Dose Replicate Study of MK0777 Gel Extrusion Module (GEM) 3 mg B.I.D. to 8 mg B.I.D. in the Treatment of Outpatients With Generalized Anxiety Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0777 (Primary)
- Indications Generalised anxiety disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Dec 2014 New trial record